Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApoAML: Venetoclax and 6-mercaptopurine in Relapsed/Refractory AML
NCT05506332Phase 1Recruiting
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax and mercaptopurine in acute myeloid leukemia (AML). Primary endpoint: Clinical Response at 2 years. Started Jul 2022; status: recruiting.
02
Drugs
venetoclaxmercaptopurine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05506332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506332.